Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ex-vivo screening platform to identify tumor-specific therapies

ABSTRACT: Ex-vivo screening platform to identify tumor-specific therapies

PROVIDER: PRJNA417676 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Ex-vivo screening platform to identify tumor-specific therapies

Project description:We report the generation of a preclinical IBC patient-derived xenograft (PDX)-derived ex vivo tumor tissue model and show that it closely replicates the tissue architecture of the original PDX tumor harvested from mice and show that its genetic signature highly correlates with that of the original tumor. We used microarrays to evaluate the robustness and reproducibility of the method used to generate the ex vivo tumor tissue model and confirm its ability to recapitulate the essential features of the original tumor.

2018-04-07 | GSE106685 | GEO

High-throughput transcriptomics platform for screening hepatotoxicants

Project description:High-throughput transcriptomics platform for screening hepatotoxicants

| PRJNA638385 | ENA

High-Throughput Transcriptomics Platform for Screening Environmental Chemicals

Project description:High-Throughput Transcriptomics Platform for Screening Environmental Chemicals

| PRJNA683595 | ENA

An ex vivo physiologic and hyperplastic vessel culture model to study intra-arterial stent therapies

Project description:An ex vivo physiologic and hyperplastic vessel culture model to study intra-arterial stent therapies

| PRJNA731919 | ENA

Ex Vivo Lung Perfusion as a Human Platform for Preclinical Small Molecule Testing

Project description:Ex Vivo Lung Perfusion as a Human Platform for Preclinical Small Molecule Testing

| PRJNA486099 | ENA

Human Ex Vivo Lung Perfusion: A Model System to study Lung diseases and direct targeted therapies

Project description:Human Ex Vivo Lung Perfusion: A Model System to study Lung diseases and direct targeted therapies

| PRJNA610580 | ENA

High-throughput transcriptomics platform for screening hepatotoxicants

Project description:We introduce a new high-throughput transcriptomics (HTTr) platform comprised of a collagen sandwich primary rat hepatocyte culture and the TempO-Seq assay for screening and prioritizing potential hepatotoxicants. We selected 14 chemicals based on their risk of drug-induced liver injury (DILI) and tested them in hepatocytes at two treatment concentrations. HTTr data was generated using the TempO-Seq whole transcriptome and S1500+ assays. The HTTr platform exhibited high reproducibility between technical replicates (r>0.9) but biological replication was greater for TempO-Seq S1500+ (r>0.85) than for the whole transcriptome (r>0.7). Reproducibility between biological replicates was dependent on the strength of transcriptional effects induced by a chemical treatment. Despite targeting a smaller number of genes, the S1500+ assay clustered chemical treatments and produced gene set enrichment analysis (GSEA) scores comparable to those of the whole transcriptome. Connectivity mapping showed a high-level of reproducibility between TempO-Seq data and Affymetrix GeneChip data from the Open TG-GATES project with high concordance between the S1500+ gene set and whole transcriptome. Taken together, our results provide guidance on selecting the number of technical and biological replicates and support the use of TempO-Seq S1500+ assay for a high-throughput platform for screening hepatotoxicants.

2021-09-01 | GSE152128 | GEO

Ex Vivo Lung Perfusion as a Human Platform for Preclinical Small Molecule Testing

Project description:We report mRNA expression from human lung homogenate samples taken during Ex Vivo Lung Perfusion during an acute challenge with LPS and an intervention with the small molecule BC1215

2018-08-16 | GSE118566 | GEO

A phenotypic screening platform for identifying chemical modulators of astrocyte reactivity

Project description:This SuperSeries is composed of the SubSeries listed below. Disease, injury, and aging induce pathological reactive astrocyte states that contribute to neurodegeneration. Modulating reactive astrocytes therefore represents an attractive therapeutic strategy. Here, we describe the development of an astrocyte phenotypic screening platform for identifying chemical modulators of astrocyte reactivity. Leveraging this platform for chemical screening, we identify HDAC3 inhibitors as effective suppressors of pathological astrocyte reactivity. We demonstrate that HDAC3 inhibition reduces molecular and functional characteristics of reactive astrocytes in vitro. Transcriptional and chromatin mapping studies show that HDAC3 inhibition disarms pathological astrocyte gene expression and function while promoting the expression of genes associated with beneficial astrocytes. Administration of RGFP966, a small molecule HDAC3 inhibitor, blocks reactive astrocyte formation and promotes neuroprotection in vivo in mice. Collectively, these results establish a platform for discovering modulators of reactive astrocyte states, inform the mechanisms that control astrocyte reactivity, and demonstrate the therapeutic benefits of modulating astrocyte reactivity for neurodegenerative diseases.

2024-01-10 | GSE185215 | GEO

CARPOOL: A library-based platform to rapidly identify next generation chimeric antigen receptors

Project description:CD19-targeted CAR therapies have successfully treated B cell leukemias, but many responders later relapse or experience toxicities. CAR ICDs are key to converting antigen recognition into anti-tumor effector functions. Despite the many possible immune signaling domain combinations that could be included in CARs, almost all CARs currently rely upon CD3, CD28, and/or 4-1BB signaling. To explore the signaling potential of CAR ICDs, we generated a library of 700,000 CD19 CAR molecules with diverse signaling domains and developed a high throughput screening platform to enable optimization of CAR signaling for anti-tumor functions. Our strategy identifies CARs with novel signaling domains that elicit distinct T cell behaviors from a clinically available CAR, including enhanced proliferation and persistence, lower exhaustion, potent cytotoxicity in an in vitro tumor rechallenge condition, and comparable tumor control in vivo. This approach is readily adaptable to numerous disease models, cell types, and selection conditions, making it a promising tool for rapidly improving adoptive cell therapies and expanding their utility to new disease indications.

2021-07-13 | GSE179767 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data